Trial Profile
Randomized Clinical Comparison of the Endeavor [zotarolimus] and the Cypher [sirolimus] Coronary Stents in Non-Selected Angina Pectoris Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2019
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms SORT-OUT-III
- 06 Nov 2019 Results of subgroup analysis evaluating 10-year performance of sirolimus-eluting cypher stent and zotarolimus-eluting endeavor stent released in the American Journal of Cardiology
- 31 Oct 2018 The SORT OUT III 10-year results will be reported at the ESC Congress. The subgroup analysis assessing 10 year outcomes in patients with or without diabeties has not yet been analyzed but will be ready for presentation at TCT as per trial design presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 25 Sep 2018 Trial design presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics